비교리스트

 카트 문의
시장보고서
상품코드
1563967

세계의 세포주 개발 시장

Cell Line Development
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 193 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세포주 개발 시장은 2030년까지 164억 달러에 달할 전망입니다.

2023년에 91억 달러로 추정된 세포주 개발 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 8.9%로 성장하고, 2030년에는 164억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 포유류 세포주 개발은 복합 연간 성장률(CAGR) 9.6%로 성장을 지속하고, 분석 기간이 끝날 때까지 131억 달러에 달할 것으로 예측됩니다. 비포유류 세포주 개발 부문의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 6.2%로 추정됩니다.

미국 시장은 25억 달러로 추정, 중국은 복합 연간 성장률(CAGR) 8.2%로 성장할 것으로 예측됩니다.

미국의 세포주 개발 시장은 2023년 25억 달러로 추정됐습니다. 세계의 2위 경제대국인 중국은 2023년부터 2030년의 분석 기간에 복합 연간 성장률(CAGR) 8.2%를 넘어 2030년까지 25억 달러 규모에 이를 것으로 예측되고 있습니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR)은 각각 8.3%와 7.2%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 약 7.0%로 성장할 것으로 예측됩니다.

세계의 세포주 개발 시장 - 주요 동향과 촉진요인

세포주 개발이란 무엇이며 왜 현대 생명 공학에서 중요한가?

세포주 개발은 생명공학에서 중요한 과정으로, 연구, 치료 및 산업 목적을 위해 균일한 유전자 구조를 가진 세포군-세포주가 생성됩니다. 이 과정은 바이오의약품, 백신, 재조합 단백질을 제조하기 위한 기본이며, 암, 자가면역질환, 유전적 결손을 포함한 다양한 질환의 치료에 이용됩니다. 이러한 세포주를 만들기 위해 과학자들은 일반적으로 조직과 유기체에서 세포를 분리하고 높은 생산성, 안정성, 환경 스트레스에 대한 내성 등 특정 특성을 유지하도록 조작합니다. 선택된 세포는 시험관 내에서 확장되어 특정 연구 및 제조 기준을 충족하는 능력이 있는지 여부를 스크리닝하고 장기 사용을 위해 세포주로 수립됩니다. 결국 이러한 세포주는 창약, 독성 시험, 유전학 연구에 필수적인 도구가 될 것입니다. 세포주는 생물학적 메커니즘 연구에서 중요한 역할을 하며, 과학자들에게 단백질, 유전자 및 기타 세포 성분의 거동을 제어된 환경에서 관찰하기 위한 플랫폼을 제공합니다. 예측 가능한 방식으로 세포를 조작하고 조사하는 이 능력은 맞춤형 의료, 유전자 치료, 재생 의료의 진보를 가속화하고 있습니다. 또한, 세포주 개발은 단클론항체와 같은 복잡한 분자인 생물학적 제제의 제조가 재현 가능하고 확장 가능하다는 것을 보장합니다. 그 결과, 의약품부터 화장품, 농업에 이르기까지 많은 산업에서 바이오 제조 공정의 기반으로 사용되고 있습니다.

세포주 개발에 영향을 미치는 최신 기술 진보란?

최근 기술의 진보는 세포주 개발 과정에 혁명을 가져옵니다. CRISPR-Cas9 유전자 편집 도구의 통합은 세포 변형의 정확성을 획기적으로 향상시키고 과학자들은 탁월한 정확도로 특정 유전자를 녹아웃하거나 삽입할 수 있습니다. 이에 의해 특히 정밀한 분자 구조를 필요로 하는 치료용 단백질의 생산에 있어서, 세포주의 응용 범위가 넓어졌습니다. 또한, 자동화와 로봇 공학은 개발 과정에서 점점 더 중요해지고 있으며, 세포주의 고처리량 스크리닝을 가능하게 하고 있습니다. 자동화 시스템은 수천 개의 세포를 약간의 시간에 스크리닝하는 효율성을 향상시킬 뿐만 아니라 인적 오류를 줄이고 결과의 일관성을 높일 수 있습니다. 또 다른 혁신적인 기술은 인공지능(AI) 및 머신러닝의 응용입니다. 이러한 도구는 현재 세포의 거동을 예측하고, 세포 배양 조건을 최적화하고, 높은 생산 세포주의 선택 과정을 간소화하기 위해 채택되었습니다. 생물학적 실험에서 생성된 엄청난 데이터 세트를 분석함으로써 AI 알고리즘은 패턴을 파악하고 견고한 세포주 개발에 필요한 시간을 대폭 단축할 것을 권장합니다. 이러한 계산 툴과 생물학적 시스템의 통합은 세포주 개발의 속도와 정밀도를 재정의할 것으로 기대되고 개발 기간이 50% 단축될 가능성을 나타내는 연구도 있습니다. 생물제제 수요가 증가하고 바이오의약품업계가 시장 투입까지의 시간을 단축하는 것을 추진하는 가운데 이러한 기술 혁신은 매우 중요합니다.

세포주 개발에서 직면하는 과제와 그 극복 방법이란?

진보에도 불구하고, 세포주 개발 과정에는 신중한 검토가 필요한 과제가 쌓여 있습니다. 주요 어려움 중 하나는 유전적으로 동일한 세포조차도 세포 거동에 고유 한 변동이 있다는 것입니다. 이 변동은 생물학적 제형의 확장성에 영향을 미칩니다. 이를 해결하기 위해 개발자는 클론 선택 기술과 마스터 세포 뱅크의 설립에 의존하고 있으며, 거기에는 안정적인 고성능 클론이 보존되어 대량 생산시 일관된 생산량을 확보하기 위해 장기적으로 모니터링됩니다. 그러나 이러한 전략을 사용하더라도 유전적 드리프트와 불안정성의 위험이 남아 있기 때문에 지속적인 모니터링과 엄격한 품질 관리가 필요합니다. 또 다른 중요한 장애물은 세포주 개발의 시간 집약적인 특성입니다. 이 긴 기간은 임상시험을 늦추고 의약품 개발 과정 전체를 늦출 수 있습니다. 기업은 현재 타임라인을 가속화하기 위한 프로세스 강화 전략에 주력하고 있습니다. 예를 들어, 단일 청소년 생물반응기와 관류 기반 배양은 품질을 손상시키지 않고 세포주 생산성을 향상시키는 데 사용됩니다. 이러한 기술과 함께 혁신적인 세포주 기술에서 유래한 바이오의약품의 신속한 승인 경로를 지원하기 위해 규제 프레임워크도 진화하고 있습니다. 그러나 제조 및 품질 관리 기준(GMP)을 엄격하게 준수해야 할 필요성은 여전히 중요한 체크 포인트입니다.

세포주 개발 시장은 어떻게 진화하고 무엇이 시장 성장 촉진요인이 되고 있는가?

세포주 개발 시장의 성장에는 몇 가지 요인이 있으며, 각각이 이러한 생명 공학 도구에 대한 수요의 급증에 기여합니다. 주요 원동력 중 하나는 암이나 당뇨병 등 만성 질환의 만연이 확대되고 있기 때문에 제약회사는 생물학적 요법에 다액의 투자를 실시하게 되어 있습니다. 단클론항체 및 기타 생물학적 제제가 최전선의 치료가 되고 있는 지금, 효율적이고 생산성이 높은 세포주에 대한 필요성은 과거에는 없을 정도로 높아지고 있습니다. 또 다른 큰 원동력은 바이오시밀러(이미 승인된 생물학적 제형과 매우 유사한 생물학적 제형)에 대한 수요의 급증입니다. 많은 대형 히트 생물 제제의 특허가 끊어진 가운데, 비용 효율적인 바이오시밀러의 개발 경쟁이 세포주 개발 기술에 대한 투자에 박차를 가하고 있습니다. 맞춤형 의료, 특히 종양학의 상승도 시장을 밀어 올리고 있습니다. 개인화 치료는 종종 환자 고유의 세포주를 생산해야 하며, 유전 공학 및 맞춤형 세포 배양 기술의 혁신을 촉진하고 있습니다. 또한 암에 대한 CAR-T 요법과 같은 세포 및 유전자 치료의 출현은 표적 치료에 사용할 수 있는 고도의 세포주의 필요성을 가속화하고 있습니다. 또한 생명공학의 연구개발에 대한 정부 자금 증가와 자동화 시스템과 AI를 탑재한 시스템의 채용 확대가 함께 소규모 생명공학 기업 시장 진입을 가능하게 하여 경쟁과 혁신을 더욱 촉진하고 있습니다. 마지막으로 화장품, 식품제조, 환경과학 등 비의약품 분야에서의 세포주 사용 확대로 이러한 기술의 범위와 응용이 확대되고 있으며, 세포주 개발은 생명공학 업계의 주요 성장 분야가 되고 있습니다.

조사 대상 기업 예(주목 44사)

  • Abzena PLC
  • American Type Culture Collection(ATCC)
  • Apath LLC
  • Bioceros
  • Catalent, Inc.
  • CELLforCURE
  • Cobra Biologics
  • Corning, Inc.
  • Cyagen US Inc.
  • Cytovance Biologics
  • Epistem Holdings PLC
  • EuBiologics Co., Ltd.
  • GE Healthcare
  • GVK Biosciences Private Limited
  • Hitachi Chemical Advanced Therapeutics Solutions, LLC
  • Lonza Group Ltd.
  • MilliporeSigma
  • NAEJA-RGM Pharmaceuticals, Inc.
  • Paragon Bioservices, Inc.
  • Patheon, Inc.
  • Promocell GmbH
  • Samsung BioLogics
  • Sartorius AG
  • Selexis SA
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

BJH 24.10.08

Global Cell Line Development Market to Reach US$16.4 Billion by 2030

The global market for Cell Line Development estimated at US$9.1 Billion in the year 2023, is expected to reach US$16.4 Billion by 2030, growing at a CAGR of 8.9% over the analysis period 2023-2030. Mammalian Cell Line Development, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$13.1 Billion by the end of the analysis period. Growth in the Non-Mammalian Cell Line Development segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.5 Billion While China is Forecast to Grow at 8.2% CAGR

The Cell Line Development market in the U.S. is estimated at US$2.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.3% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.0% CAGR.

Global Cell Line Development Market - Key Trends and Drivers Summarized

What Is Cell Line Development and Why Does It Matter in Modern Biotechnology?

Cell line development is a crucial process in biotechnology where cell lines—groups of cells with a uniform genetic structure—are generated for research, therapeutic, and industrial purposes. This process is fundamental for producing biopharmaceuticals, vaccines, and recombinant proteins, which are used to treat a variety of diseases, including cancer, autoimmune disorders, and genetic deficiencies. To create these cell lines, scientists typically isolate cells from tissues or organisms and then engineer them to maintain specific properties, such as high productivity, stability, or resistance to environmental stress. The selected cells are expanded in vitro, screened for their ability to meet specific research or manufacturing criteria, and then established as cell lines for long-term use. Over time, these cell lines become integral tools in drug discovery, toxicity testing, and genetic research. Cell lines play a vital role in the study of biological mechanisms, offering scientists a platform to observe the behavior of proteins, genes, and other cellular components in controlled environments. This ability to manipulate and examine cells in a predictable manner has accelerated advancements in personalized medicine, gene therapy, and regenerative medicine. Moreover, cell line development ensures that the manufacturing of biologics—complex molecules like monoclonal antibodies—is reproducible and scalable. As a result, it serves as the foundation of biomanufacturing processes across numerous industries, from pharmaceuticals to cosmetics and agriculture.

What Are the Latest Technological Advancements Impacting Cell Line Development?

Recent advancements in technology are revolutionizing the process of cell line development. The integration of CRISPR-Cas9 gene-editing tools has drastically improved the precision of cell modifications, enabling scientists to knock out or insert specific genes with unmatched accuracy. This has broadened the scope of applications for cell lines, particularly in the production of therapeutic proteins that require precise molecular structures. Additionally, automation and robotics are becoming increasingly important in the development process, allowing for high-throughput screening of cell lines. Automated systems not only improve the efficiency of screening thousands of cells in a fraction of the time, but they also reduce human error, leading to higher consistency in results. Another transformative technology is the application of artificial intelligence (AI) and machine learning. These tools are now being employed to predict cell behavior, optimize cell culture conditions, and streamline the selection process for high-producing cell lines. By analyzing vast datasets generated from biological experiments, AI algorithms can identify patterns and make recommendations that significantly cut down the time needed to develop robust cell lines. This integration of computational tools with biological systems is expected to redefine the speed and accuracy of cell line development, with some studies indicating a potential 50% reduction in development timelines. Such innovations are critical as the demand for biologics grows and the biopharmaceutical industry pushes for faster time-to-market.

What Are the Challenges Faced in Cell Line Development and How Are They Overcome?

Despite the advancements, the cell line development process is still fraught with challenges that require careful consideration. One of the primary difficulties is the inherent variability in cellular behavior, even among genetically identical cells. This variability can lead to inconsistent production yields, which affects the scalability of biologic drugs. To address this, developers are increasingly relying on clonal selection techniques and the establishment of master cell banks, where stable, high-performing clones are stored and monitored over time to ensure consistent output during mass production. However, even with these strategies, the risk of genetic drift or instability remains, necessitating ongoing monitoring and stringent quality control. Another significant hurdle is the time-intensive nature of cell line development, which traditionally takes anywhere from 6 to 12 months. This extended timeframe can delay clinical trials and slow the overall drug development process. Companies are now focusing on process intensification strategies to accelerate timelines. For example, single-use bioreactors and perfusion-based cultures are being used to improve the productivity of cell lines without compromising quality. In tandem with these techniques, regulatory frameworks are evolving to support faster approval pathways for biopharmaceuticals derived from innovative cell line technologies. Yet, the need for stringent compliance with Good Manufacturing Practices (GMP) remains a critical checkpoint, as any lapse in quality can lead to costly setbacks in production.

How Is the Market for Cell Line Development Evolving, and What Are the Growth Drivers?

The growth in the cell line development market is driven by several factors, each contributing to the rapidly expanding demand for these biotechnological tools. One of the primary drivers is the increasing prevalence of chronic diseases, such as cancer and diabetes, which are prompting pharmaceutical companies to invest heavily in biologic therapies. With monoclonal antibodies and other biologics becoming frontline treatments, the need for efficient, high-producing cell lines has never been greater. Another significant driver is the surge in demand for biosimilars—biological products that are highly similar to already approved biologics. As patents for many blockbuster biologics expire, the race to develop cost-effective biosimilars is fueling investment in cell line development technologies. The rise of personalized medicine, particularly in oncology, is also pushing the market forward. Personalized therapies often require the production of patient-specific cell lines, driving innovations in genetic engineering and custom cell culture techniques. In addition, the emergence of cell and gene therapies, such as CAR-T therapy for cancer, is accelerating the need for advanced cell lines that can be used to deliver targeted treatments. Furthermore, increasing government funding for research and development in biotechnology, coupled with the growing adoption of automated and AI-powered systems, is enabling smaller biotech firms to enter the market, further driving competition and innovation. Lastly, the expanding use of cell lines in non-pharmaceutical sectors, such as cosmetics, food production, and environmental sciences, is broadening the scope and applications of these technologies, making cell line development a key growth area in the biotech industry.

Select Competitors (Total 44 Featured) -

  • Abzena PLC
  • American Type Culture Collection (ATCC)
  • Apath LLC
  • Bioceros
  • Catalent, Inc.
  • CELLforCURE
  • Cobra Biologics
  • Corning, Inc.
  • Cyagen US Inc.
  • Cytovance Biologics
  • Epistem Holdings PLC
  • EuBiologics Co., Ltd.
  • GE Healthcare
  • GVK Biosciences Private Limited
  • Hitachi Chemical Advanced Therapeutics Solutions, LLC
  • Lonza Group Ltd.
  • MilliporeSigma
  • NAEJA-RGM Pharmaceuticals, Inc.
  • Paragon Bioservices, Inc.
  • Patheon, Inc.
  • Promocell GmbH
  • Samsung BioLogics
  • Sartorius AG
  • Selexis SA
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Cell Line Development - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Biologics and Biosimilars Expands Market for Cell Line Development
    • Advancements in Gene Editing Technologies Propel Growth in Cell Line Engineering
    • Growing Adoption of Cell-Based Therapies Drives Demand for Efficient Cell Line Development
    • Automation in Cell Line Selection Spurs Efficiency and Scalability in Biopharmaceutical Production
    • Expansion of Monoclonal Antibody Production Boosts Market for Stable Cell Lines
    • Innovations in CRISPR and Gene Editing Create New Opportunities in Cell Line Development
    • Rising Investment in Cancer Research Fuels Demand for Custom Engineered Cell Lines
    • Growing Use of Cell Line Development in Vaccine Production Accelerates Market Growth
    • Advances in Single-Cell Analysis and Omics Technologies Propel Innovation in Cell Line Development
    • Emerging Applications in Gene Therapy and Regenerative Medicine Create New Growth Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cell Line Development Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cell Line Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Cell Line Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Mammalian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Mammalian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Non-Mammalian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Non-Mammalian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Reagents & Media by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Reagents & Media by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Accessories & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Accessories & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Bioproduction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Bioproduction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Tissue Engineering & Regenerative medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Tissue Engineering & Regenerative medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Toxicity Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World 7-Year Perspective for Toxicity Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 25: World 7-Year Perspective for Recombinant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hybridomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World 7-Year Perspective for Hybridomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Continuous Cell Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World 7-Year Perspective for Continuous Cell Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Primary Cell Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 31: World 7-Year Perspective for Primary Cell Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 35: USA 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 37: USA 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • CANADA
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Canada 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Canada 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Canada 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • JAPAN
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Japan 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 53: Japan 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Japan 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • CHINA
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 59: China 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 61: China 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • EUROPE
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Cell Line Development by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 65: Europe 7-Year Perspective for Cell Line Development by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Europe 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Europe 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Europe 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • FRANCE
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 77: France 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 79: France 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • GERMANY
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Germany 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Germany 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Germany 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • ITALY
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Italy 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Italy 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 95: Italy 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 97: Italy 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • UNITED KINGDOM
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 98: UK Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: UK 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 101: UK 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 103: UK 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UK 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Cell Line Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of World 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2024 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Cell Line Development by Component - Reagents & Media, Equipment and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 125: Rest of World 7-Year Perspective for Cell Line Development by Component - Percentage Breakdown of Value Sales for Reagents & Media, Equipment and Accessories & Consumables for the Years 2024 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Cell Line Development by Application - Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 127: Rest of World 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Drug Discovery, Tissue Engineering & Regenerative medicine, Research and Toxicity Testing for the Years 2024 & 2030
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of World 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제